Every material Form 8-K TScan Therapeutics, Inc. has filed with the SEC since September 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TScan Therapeutics disclosed that directors Garry Nicholson and Gabriela Gruia, M.D., resigned from its Board of Directors and all board committees, effective October 13, 2026, with no disagreement with the company cited. The board filled the vacancies on its committees, appointing Stephen Biggar and R. Keith Woods to the Nominating and Corporate Governance Committee, which matters to shareholders as a change in board composition and committee makeup.
Garry Nicholson and Gabriela Gruia, M.D., resigned from the board and all committees effective October 13, 2026.
The filing states the resignations were not due to any disagreement with the company on operations, practices or policies.
Stephen Biggar (member) and R. Keith Woods (chairperson) were appointed to the Nominating and Corporate Governance Committee effective October 13, 2026.
The Audit Committee now consists of Katina Dorton, Barbara Klencke and R. Keith Woods.
TScan Therapeutics said its Chief Financial Officer, Jason A. Amello, and Chief Medical Officer, Chrystal Louis, will leave the company as part of a strategic reorganization. Both executives signed separation agreements, with employment ending on the earlier of November 1, 2026 or the date they start other paid work, and their pay and benefits continue until then.
Jason A. Amello (CFO) and Chrystal Louis, M.D., MPH (CMO) are departing under separation agreements dated September 24 and September 25, 2026.
Employment ends on the earlier of November 1, 2026 or the executive's start of other employment, consulting or paid board service.
Amello may receive a $85,000 lump-sum cash award and Louis a $125,000 award, each payable if a company milestone is achieved before their separation date under the November 2025 retention program.
TScan Therapeutics' Compensation Committee approved a key employee retention program on September 8, 2026, covering CEO Gavin MacBeath and Chief Legal and Strategy Officer Zoran Zdraveski. The program provides cash awards and potential future equity grants, with part of the cash tied to a clinical milestone and the equity tied to a financing milestone.
Dr. MacBeath cash award of $822,000; Dr. Zdraveski cash award of $416,000
Dr. MacBeath to receive 2,400,000 RSUs; Dr. Zdraveski to receive 1,050,000 RSUs under the 2021 Plan
One-third of the first half of cash awards paid in November 2026, two-thirds in February 2027; second half tied to a clinical milestone
One-third of RSUs vest on a financing milestone; remaining two-thirds vest over first and second anniversaries of that milestone
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TScan Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →